Welcome to our dedicated page for Ideaya Biosciences SEC filings (Ticker: IDYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IDEAYA Biosciences, Inc. (NASDAQ: IDYA) SEC filings page aggregates the company’s regulatory disclosures, including current reports on Form 8-K and other Exchange Act filings. These documents provide structured information on material events, financial results, collaborations, and governance decisions that affect the precision oncology business.
IDEAYA uses Form 8-K to report key developments such as quarterly financial results, material licensing agreements, and changes in major collaborations. For example, 8-K filings describe the exclusive license agreement with Servier for rights to darovasertib outside the United States, GlaxoSmithKline’s election to terminate a collaboration covering the Werner Helicase (IDE275) and Pol Theta (IDE705) programs, and positive clinical data from trials of darovasertib, IDE849, and IDE397. Other 8-Ks document annual meeting voting results, executive appointments, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4).
Filings also identify IDEAYA’s listing on The Nasdaq Global Select Market under the symbol IDYA and confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934. Investors can review these filings to understand how IDEAYA structures its collaborations, recognizes collaboration revenue, and discloses pipeline milestones and regulatory interactions.
On Stock Titan, IDEAYA’s SEC filings are updated as they are posted to EDGAR and can be paired with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly scan material terms of agreements, track clinical and regulatory updates reported under Item 8.01, and monitor financial disclosures reported under Item 2.02, without having to parse every line of the original filing.
IDEAYA Biosciences, Inc. furnished a current report describing that it announced its financial results for the third quarter ended September 30, 2025. The company did this through a press release dated November 4, 2025, which is included as Exhibit 99.1.
The report clarifies that the earnings information and the press release are being furnished, not filed, so they are not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.
IDEAYA Biosciences (IDYA) reported new Phase 2 clinical outcomes for its darovasertib plus crizotinib combination in first-line metastatic uveal melanoma. In 44 patients with a median follow-up of 25 months (cut-off May 28, 2025), the trial observed a median overall survival of 21.1 months and median progression-free survival of 7.0 months. Among 41 efficacy-evaluable patients, the confirmed overall response rate was 34% (14/41) with a 9.0‑month median duration of response, and disease control reached 90% (37/41). Historical median overall survival in treatment‑naïve mUM is approximately 12 months.
The regimen showed manageable tolerability; the most common treatment‑related adverse events (>30%) were diarrhea, nausea, edema, vomiting, dermatitis, hypoalbuminemia and fatigue, with grade ≥3 events of iron‑deficiency anemia and pulmonary embolism (both 5%). IDEAYA is running a registration‑enabling Phase 2/3 trial (OptimUM‑02) targeting median PFS readout by year‑end 2025 to Q1 2026, and a Phase 3 neoadjuvant trial (OptimUM‑10) in primary uveal melanoma. Pfizer is supplying defined quantities of crizotinib under a collaboration and supply agreement.
IDEAYA Biosciences (IDYA) reported new Phase 2 clinical outcomes for its darovasertib plus crizotinib combination in first-line metastatic uveal melanoma. In 44 patients with a median follow-up of 25 months (cut-off May 28, 2025), the trial observed a median overall survival of 21.1 months and median progression-free survival of 7.0 months. Among 41 efficacy-evaluable patients, the confirmed overall response rate was 34% (14/41) with a 9.0‑month median duration of response, and disease control reached 90% (37/41). Historical median overall survival in treatment‑naïve mUM is approximately 12 months.
The regimen showed manageable tolerability; the most common treatment‑related adverse events (>30%) were diarrhea, nausea, edema, vomiting, dermatitis, hypoalbuminemia and fatigue, with grade ≥3 events of iron‑deficiency anemia and pulmonary embolism (both 5%). IDEAYA is running a registration‑enabling Phase 2/3 trial (OptimUM‑02) targeting median PFS readout by year‑end 2025 to Q1 2026, and a Phase 3 neoadjuvant trial (OptimUM‑10) in primary uveal melanoma. Pfizer is supplying defined quantities of crizotinib under a collaboration and supply agreement.
IDEAYA Biosciences filed an Form 8-K reporting material event updates tied to its OptimUM-10 trial of darovasertib. The company states that all efficacy-evaluable patients had received three or more cycles of treatment and had both baseline and on-treatment tumor assessments, paired dosimetry, and visual acuity score data available as of the stated cut-off. A median or representative follow-up duration of 3.5 months is reported for post-baseline scans, and the filing notes the study has not yet achieved a fully mature confirmed overall response rate (ORR%). The 8-K references the company’s 10-K and other SEC reports and is signed by Yujiro Hata, President and CEO.
IDEAYA Biosciences filed an Form 8-K reporting material event updates tied to its OptimUM-10 trial of darovasertib. The company states that all efficacy-evaluable patients had received three or more cycles of treatment and had both baseline and on-treatment tumor assessments, paired dosimetry, and visual acuity score data available as of the stated cut-off. A median or representative follow-up duration of 3.5 months is reported for post-baseline scans, and the filing notes the study has not yet achieved a fully mature confirmed overall response rate (ORR%). The 8-K references the company’s 10-K and other SEC reports and is signed by Yujiro Hata, President and CEO.
IDEAYA Biosciences, Inc. disclosed that an upfront payment together with expected cost savings from an agreement are expected to extend the company’s cash runway by at least twelve months and, based on the company’s current operating plan, fund planned operations into 2030. The filing references mid-teens to low-twenties percentages in the text but does not provide further detail on what those percentages measure. The company also notes its 10-K was filed with the SEC on February 18, 2025. The report is signed by Yujiro Hata, President and Chief Executive Officer, dated September 2, 2025.
Janus Henderson Group plc filed Amendment No. 4 to a Schedule 13G reporting its beneficial ownership of IDEAYA BIOSCIENCES, INC. common stock (CUSIP 45166A102). The filing lists an aggregate beneficial ownership of 6,206,238 shares, representing 6.9% of the class, tied to an event date of 06/30/2025. The report shows no sole voting or dispositive power and shared voting and dispositive power of 6,206,238 shares, while Item 4 separately notes that JHIUS may be deemed beneficial owner of 6,080,532 shares. The reporting person is identified as an investment adviser/holding company (IA, HC). The statement is signed by Kristin Mariani on 08/14/2025 and includes a Power of Attorney exhibit dated 12/09/2022.
Capital Research Global Investors reports beneficial ownership of 6,552,691 shares of IDEAYA Biosciences common stock, representing 7.5% of the 87,581,963 shares the filing states are outstanding. The disclosure is made on a Schedule 13G and includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer.
The filing shows CRGI has sole voting and sole dispositive power over the reported shares and names SMALLCAP World Fund, Inc. as an account on whose behalf shares are held. No group affiliation or intent to seek control is indicated in the statement.
SEC Form 3 filing for IDEAYA Biosciences (IDYA): Newly appointed Chief Financial Officer Joshua Bleharski has disclosed his initial beneficial ownership. The filing shows 250,000 stock options with an exercise price of $20.05 per share. Vesting begins 25 % on May 1 2026, with the remaining shares vesting monthly in equal installments over 36 months, reaching full vesting by May 1 2029. No non-derivative common shares are reported at this time, and the options are held directly. This Form 3 is procedural, establishing the CFO’s ownership under Section 16(a) of the Exchange Act; it does not include financial performance data or indicate any corporate transactions.